GLUE (Monte Rosa Therapeutics) Total Inventories: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLUE Monte Rosa Therapeutics Inc GLUE
34 GF Score
Price $21.97
! 5 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics Total Inventories?

Monte Rosa Therapeutics GLUE -4.52% 34 Total Inventories is $0.00 Mil as of Mar. 2026. GuruFocus rates GLUE with a GF Score™ of 34/100. The stock has 5 warning signs investors should review.

Monte Rosa Therapeutics's total inventories for the quarter that ended in Mar. 2026 was $0.00 Mil. Monte Rosa Therapeutics's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Monte Rosa Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $5.36.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Monte Rosa Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.00.

Monte Rosa Therapeutics  (NAS:GLUE) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Monte Rosa Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is

Net-Net Working Capital Per Share (Q: Mar. 2026 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(666.22+0.75 * 0+0.5 * 0-214.512
-0-0)/84.322
=5.36

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Monte Rosa Therapeutics's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Monte Rosa Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2026 ) / Average Total Inventories (Q: Mar. 2026 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Monte Rosa Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=0 / 4.21
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Monte Rosa Therapeutics Total Inventories Related Terms

Monte Rosa Therapeutics Total Inventories Historical Data

* Premium members only.

The historical data trend for Monte Rosa Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monte Rosa Therapeutics Total Inventories Chart

Monte Rosa Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Monte Rosa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GLUE
34GF Score
Monte Rosa Therapeutics Inc GLUE
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monte Rosa Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.00 Mil mean?
Monte Rosa Therapeutics (GLUE) has a Total Inventories of $0.00 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Monte Rosa Therapeutics and its competitors.
Is Monte Rosa Therapeutics' Total Inventories too high?
Monte Rosa Therapeutics' current Total Inventories is $0.00 Mil. Overall, Monte Rosa Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' Total Inventories compare to SNDX and IOVA?
Monte Rosa Therapeutics' Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Monte Rosa Therapeutics and its competitors. Monte Rosa Therapeutics's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. Monte Rosa Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current Total Inventories is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
34GF Score

Get the complete analysis for GLUE

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.97
Price